---
title: "Astrazeneca Treasury Limited — Ownership Dossier"
canonical: https://whiteintel.dev/entity/7f4279b9-5df2-4e84-9390-1359ded0a5a4
json: https://whiteintel.dev/api/public/dossier/7f4279b9-5df2-4e84-9390-1359ded0a5a4
identifier: gb-coh:2910116
jurisdiction: GB
risk: Low
source: WhiteIntel corporate-ownership graph
---

# Astrazeneca Treasury Limited

**Type:** Company  
**Jurisdiction:** [GB](https://whiteintel.dev/jurisdictions/gb)  
**Identifier:** `gb-coh:2910116`  
**Risk level:** Low  
**Canonical dossier:** https://whiteintel.dev/entity/7f4279b9-5df2-4e84-9390-1359ded0a5a4  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/7f4279b9-5df2-4e84-9390-1359ded0a5a4  

## Cross-source identity

The same real-world entity, resolved across sources:

- **ASTRAZENECA TREASURY LIMITED** — companies_house_bulk · `oo:GB-COH-02910116` — https://whiteintel.dev/entity/2763a136-67ee-56fe-abd4-5d5b1cf5dbff
- **ASTRAZENECA TREASURY LIMITED** — GLEIF · `lei:213800RVA6CA8HN1RT89` — https://whiteintel.dev/entity/d57fa06e-701a-57bd-9294-d4c95a1b1571

## Ownership & control

### Holdings / subsidiaries

- **AZENCO4 LIMITED** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/302f2d13-68e9-5a0f-803e-c8cc496f6814
- **CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/c678c471-d990-534c-9fa7-2b102658f290
- **ZENECA FINANCE (NETHERLANDS) COMPANY** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/025add90-4941-5151-a8d9-34a31fe00317
- **Entasis Therapeutics Holdings Inc.** (beneficial owner) — 37.5% — https://whiteintel.dev/entity/685b5ea2-e329-55ac-9b56-da64c5416b43
- **ZENCO (NO. 8) LIMITED** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/3dfe0141-ab86-5656-92ab-fabaf0f08843
- **AZENCO5 LIMITED** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/9f601de7-25b4-5a1c-9866-c8e0d060f220
- **AZENCO6 LIMITED** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/f93bc8b3-da3d-52e4-be92-ca4421852567
- **MEDIMMUNE U.K. LIMITED** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/f32a9b71-df4b-476d-80e4-38a73b03884b

### UBO chain (walk to the ultimate owner)

A **8-step** ownership/control chain to the ultimate beneficial owner is resolved for this entity. The full cited chain unlocks with a paid API key or a one-off dossier — https://whiteintel.dev/pricing.

## Get the full, resolved dossier (agent-callable)

The above is the free teaser. The resolved **multi-hop UBO chain**, ownership **%**, full **financial history**, itemised **assets** and the hop-by-hop **exposure path** are the paid depth — callable as tools from your agent:

```bash
npx -y @whiteintel/mcp-server   # then: get_dossier · trace_ownership_path · check_offshore_exposure
```

Or unlock a one-off cited dossier for **Astrazeneca Treasury Limited** — https://whiteintel.dev/entity/7f4279b9-5df2-4e84-9390-1359ded0a5a4 · pricing https://whiteintel.dev/pricing.

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **Astrazeneca Treasury Limited**. Human view: https://whiteintel.dev/entity/7f4279b9-5df2-4e84-9390-1359ded0a5a4 · Structured JSON: https://whiteintel.dev/api/public/dossier/7f4279b9-5df2-4e84-9390-1359ded0a5a4._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._